Central melanocortin receptor agonist reduces spontaneous and scheduled meal size but does not augment duodenal preload-induced feeding inhibition.

Azzara AV, Sokolnicki JP, Schwartz GJ

Physiology & behavior1 Nov 2002Cited by 54 (Europe PMC)

PMID12419417DOI10.1016/s0031-9384(02)00883-1PepBankPUB-12419417

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In male rats, central MTII reduced subsequent glucose intake during scheduled access to liquid glucose.
In plain wordsIn rats, MTII given in the brain reduced how much glucose solution they drank.
Peptide
Melanotan II
Outcome
DecreaseGlucose intake during scheduled access
Study
ratn: not reported in source
Male Sprague-Dawley rats
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
0.01-1.0 nmol · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
and MTII reduced subsequent glucose intake.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined meal patterns and intake in male Sprague-Dawley rats following central intracerebroventricular administration of MTII (0.01-1.0 nmol)
Report a problemFND-1241941701
02AnimalAnimal study (in vivo)Efficacy outcome
In male rats, no dose of MTII augmented the reduction in food intake produced by duodenal glucose alone.
In plain wordsIn rats, MTII did not add to the intake-lowering effect of glucose placed in the gut.
Peptide
Melanotan II
Outcome
No significant changeInteraction of MTII with duodenal glucose preload on intake
Study
ratn: not reported in source
Male Sprague-Dawley rats
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
0.01-1.0 nmol · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
However, no dose of MTII augmented the reductions in food intake produced by duodenal glucose alone.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined meal patterns and intake in male Sprague-Dawley rats following central intracerebroventricular administration of MTII (0.01-1.0 nmol)
Report a problemFND-1241941702
03AnimalAnimal study (in vivo)Efficacy outcome
In male rats with overnight chow access, MTII at 0.1 and 1.0 nmol reduced food intake.
In plain wordsIn rats, MTII reduced overnight chow intake.
Peptide
Melanotan II
Outcome
DecreaseOvernight chow intake
Study
ratn: not reported in source
Male Sprague-Dawley rats
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
0.1 and 1.0 nmol · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
During overnight access to pelleted chow, the 0.1- and 1.0-nmol doses of MTII reduced food intake, meal size, meal duration, and body weight, and increased the satiety ratio (duration of intermeal interval/preceding meal size) but did not change meal frequency.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined meal patterns and intake in male Sprague-Dawley rats following central intracerebroventricular administration of MTII (0.01-1.0 nmol)
Report a problemFND-1241941703
04AnimalAnimal study (in vivo)Efficacy outcome
In male rats with overnight chow access, MTII at 0.1 and 1.0 nmol reduced meal size.
In plain wordsIn rats, MTII made meals smaller.
Peptide
Melanotan II
Outcome
DecreaseMeal size
Study
ratn: not reported in source
Male Sprague-Dawley rats
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
0.1 and 1.0 nmol · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
During overnight access to pelleted chow, the 0.1- and 1.0-nmol doses of MTII reduced food intake, meal size, meal duration, and body weight, and increased the satiety ratio (duration of intermeal interval/preceding meal size) but did not change meal frequency.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined meal patterns and intake in male Sprague-Dawley rats following central intracerebroventricular administration of MTII (0.01-1.0 nmol)
Report a problemFND-1241941704
05AnimalAnimal study (in vivo)Efficacy outcome
In male rats with overnight chow access, MTII at 0.1 and 1.0 nmol reduced meal duration.
In plain wordsIn rats, MTII made meals shorter.
Peptide
Melanotan II
Outcome
DecreaseMeal duration
Study
ratn: not reported in source
Male Sprague-Dawley rats
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
0.1 and 1.0 nmol · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
During overnight access to pelleted chow, the 0.1- and 1.0-nmol doses of MTII reduced food intake, meal size, meal duration, and body weight, and increased the satiety ratio (duration of intermeal interval/preceding meal size) but did not change meal frequency.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined meal patterns and intake in male Sprague-Dawley rats following central intracerebroventricular administration of MTII (0.01-1.0 nmol)
Report a problemFND-1241941705
06AnimalAnimal study (in vivo)Efficacy outcome
In male rats with overnight chow access, MTII at 0.1 and 1.0 nmol reduced body weight.
In plain wordsIn rats, MTII lowered body weight.
Peptide
Melanotan II
Outcome
DecreaseBody weight
Study
ratn: not reported in source
Male Sprague-Dawley rats
Outcome group
Body weight · Metabolic and weight
Studied dose
0.1 and 1.0 nmol · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
During overnight access to pelleted chow, the 0.1- and 1.0-nmol doses of MTII reduced food intake, meal size, meal duration, and body weight, and increased the satiety ratio (duration of intermeal interval/preceding meal size) but did not change meal frequency.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined meal patterns and intake in male Sprague-Dawley rats following central intracerebroventricular administration of MTII (0.01-1.0 nmol)
Report a problemFND-1241941706
07AnimalAnimal study (in vivo)Efficacy outcome
In male rats with overnight chow access, MTII at 0.1 and 1.0 nmol increased the satiety ratio (intermeal interval divided by preceding meal size).
In plain wordsIn rats, MTII made the gap between meals longer relative to meal size.
Peptide
Melanotan II
Outcome
IncreaseSatiety ratio
Study
ratn: not reported in source
Male Sprague-Dawley rats
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
0.1 and 1.0 nmol · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
During overnight access to pelleted chow, the 0.1- and 1.0-nmol doses of MTII reduced food intake, meal size, meal duration, and body weight, and increased the satiety ratio (duration of intermeal interval/preceding meal size) but did not change meal frequency.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined meal patterns and intake in male Sprague-Dawley rats following central intracerebroventricular administration of MTII (0.01-1.0 nmol)
Report a problemFND-1241941707
08AnimalAnimal study (in vivo)Efficacy outcome
In male rats with overnight chow access, MTII did not change meal frequency.
In plain wordsIn rats, MTII did not change how often they ate.
Peptide
Melanotan II
Outcome
No significant changeMeal frequency
Study
ratn: not reported in source
Male Sprague-Dawley rats
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
0.1 and 1.0 nmol · intracerebroventricularAs given in this study (rat).
Source sentences
Summary
but did not change meal frequency.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined meal patterns and intake in male Sprague-Dawley rats following central intracerebroventricular administration of MTII (0.01-1.0 nmol)
Report a problemFND-1241941708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 09:43 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.